Moderna, Inc. — Director's Dealing 2022

Feb 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-02-09

Reporting Person: Andres Juan (See remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-09	Common Stock	M	2000	$14.22	Acquired	2000	Direct
2022-02-09	Common Stock	S	2000	$154.26	Disposed	0	Direct
2022-02-09	Common Stock	M	1740	—	Acquired	1740	Direct
2022-02-10	Common Stock	S	768	$158.892	Disposed	972	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-09	Stock Option (Right to Buy)	$14.22	M	2000	Disposed	2028-02-28	Common Stock (2000)	Direct
2022-02-09	Restricted Stock Units	$0	M	1740	Disposed		Common Stock (1740)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive
plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F4: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

F5: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.